Ixekizumab-induced alopecia areata

Eldirany, Sherif A.; Myung, Peggy; Bunick, Christopher G.

doi:10.1016/j.jdcr.2019.10.012

Cited by 12 publications

(9 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Excessive amounts of Th17 cells trigger inflammation in hair follicles, and high serum IL-17 levels are detected in patients with AA [ 8 ]. However, in certain cases, it was reported that AA develops from using IL-17 inhibitors to treat psoriasis, which can be regarded as a paradoxical reaction [ 9 , 10 ], and AA was ameliorated by switching to other biologics [ 9 ]. These reports suggest that IL-17 and Th17 cells may not play a major role in AA pathogenesis.…”

Section: Discussionmentioning

confidence: 99%

Two Cases of Cutaneous Adverse Effects Induced by Tumor Necrosis Factor-Alpha Inhibitors

et al. 2021

View full text Add to dashboard Cite

Here, we report two cases of cutaneous adverse effects possibly induced by the use of tumor necrosis factor-alpha (TNF-α) inhibitors. The first case presented alopecia areata (AA) and atopic dermatitis (AD) that developed during the treatment of ulcerative colitis using infliximab; the other case presented urticaria and AD that developed during the treatment of rheumatoid arthritis using etanercept. AA, AD, and urticaria are relatively common skin diseases; however, they are not well known as adverse effects of TNF-α inhibitors. Although immunological studies were not performed, the clinical courses suggested that these skin disorders might have developed as a result of an immune four-way imbalance in T helper 1 (Th1), Th2, Th17, and regulatory T cells by the administration of TNF-α inhibitors.

show abstract

Section: Discussionmentioning

confidence: 99%

Two Cases of Cutaneous Adverse Effects Induced by Tumor Necrosis Factor-Alpha Inhibitors

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Both patients with patchy hair loss were diagnosed with alopecia areata (AA) clinically, with a biopsy supporting the diagnosis in one case. 3 Cases of diffuse alopecia described trichoscopic features of yellow and black dots also consistent with AA (personal communication). 2 One of the four patients continued his IL-17 inhibitor after developing alopecia.…”

Section: Development Of Alopecia In Patients Treated With Interleukinmentioning

confidence: 96%

“…All reported patients had active psoriasis at baseline that resolved completely with treatment. [1][2][3] Specific medications included brodalumab (one case), secukinumab (two cases), and ixekizumab (one case). Latency to alopecia onset ranged from 2 to 13 months after the initiation of therapy (Table 1).…”

Section: Development Of Alopecia In Patients Treated With Interleukinmentioning

confidence: 99%

“…He achieved complete remission on tildrakizumab with no new episodes of alopecia. 3 Another patient was immediately switched to ustekinumab, followed by complete resolution of hair loss along with continued remission of psoriasis. 2 The remaining patient was switched from secukinumab to brodalumab.…”

Section: Development Of Alopecia In Patients Treated With Interleukinmentioning

confidence: 99%

“…4,5 In a pilot study in which seven subjects with extensive AA received secukinumab, none of the patients achieved SALT50 after 20 weeks. 5 Other biologic treatments for psoriasis, commonly tumor necrosis factor-alpha inhibitors 6 and rarely IL-12/23 inhibitors, 3 have been linked to AA. Immunomodulation by these treatments may result in immune dysregulation that cause autoimmune adverse events.…”

Section: Development Of Alopecia In Patients Treated With Interleukinmentioning

confidence: 99%

See 2 more Smart Citations